AbbVie Inc. $ABBV Shares Purchased by Westmount Partners LLC

Key Points

• Westmount Partners LLC increased its AbbVie stake by 143.4% in the first quarter, buying 7,178 additional shares and bringing its total holding to 12,184 shares worth about $2.65 million.
• AbbVie is drawing attention for a potential $10.9 billion acquisition of Apogee Therapeutics, which could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth.
• The company recently beat quarterly earnings and revenue estimates, and it also declared a $1.73 per share quarterly dividend, reinforcing its shareholder-return profile despite some litigation and stock-price pressure.

Westmount Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 143.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,184 shares of the company's stock after acquiring an additional 7,178 shares during the quarter. Westmount Partners LLC's holdings in AbbVie were worth $2,650,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ABBV. Nations Financial Group Inc. IA ADV lifted its stake in shares of AbbVie by 0.5% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 21,479 shares of the company's stock valued at $4,672,000 after purchasing an additional 103 shares during the period. Physicians Financial Services Inc. boosted its holdings in AbbVie by 1.9% during the first quarter. Physicians Financial Services Inc. now owns 12,075 shares of the company's stock worth $2,626,000 after buying an additional 225 shares in the last quarter. Brady Martz Wealth Solutions LLC grew its position in AbbVie by 21.0% during the first quarter. Brady Martz Wealth Solutions LLC now owns 8,800 shares of the company's stock valued at $1,914,000 after buying an additional 1,525 shares during the period. Aspen Investment Management Inc grew its position in AbbVie by 3.9% during the first quarter. Aspen Investment Management Inc now owns 13,279 shares of the company's stock valued at $2,888,000 after buying an additional 502 shares during the period. Finally, J. Derek Lewis & Associates Inc. purchased a new position in AbbVie in the fourth quarter valued at $4,173,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

AbbVie Stock Performance

Shares of NYSE ABBV opened at $216.63 on Monday. The firm has a fifty day moving average of $212.18 and a 200 day moving average of $218.72. The firm has a market cap of $382.74 billion, a PE ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the firm posted $2.46 earnings per share. The company's revenue was up 12.4% compared to the same quarter last year. On average, equities analysts predict that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. AbbVie's dividend payout ratio (DPR) is currently 340.89%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. William Blair reiterated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Bank of America upgraded AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 target price on the stock in a research report on Thursday, April 30th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, June 7th. BMO Capital Markets reaffirmed an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Finally, Morgan Stanley upped their price target on AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.